Johnson & Johnson will buy all outstanding shares of Japanese skincare firm Ci:z Holdings that it does not already own for $2.05 billion in cash. The acquisition will give J&J ownership of Dr.Ci:Labo, Labo Labo, and Genomer.
WHO: Ci:z Holdings Co., Ltd. is a Japanese company focused on the marketing, development, and distribution of a broad range of dermocosmetic, cosmetic, and skincare products. Johnson & Johnson is the world’s largest and most broadly based health care company.
WHY: Ownership of popular brands such as Dr.Ci:Labo, Labo Labo, and Genomer should help J&J strengthen its international innovation pipeline.
IN THEIR OWN WORDS: “Health and beauty consumers are actively seeking science-based innovation to improve their skin,” said Jorge Mesquita, worldwide chairman, Johnson & Johnson Consumer. “This transaction will maximize value creation for Johnson & Johnson’s Consumer business by bringing in an agile innovation model and rapidly accelerating sales through our global commercialization expertise.”
2 Article(s) Remaining